Researchers at the University of Notre Dame have found a way to inhibit T-cell activation by targeting nitration of an amino acid in cancer cells. This approach could enhance cancer immunotherapy by identifying activity-based markers and designing approaches that shut down specific mechanisms inhibiting T-cell activation.
A new type of molecule blocks the action of genes that drive therapy-resistant prostate cancer growth, reducing cell proliferation by 95%. The cyclic peptoids also blocked a key growth signal in live animal tests.
A new analysis of genetic data and clinical trial results suggests that African-American men may have comparatively higher cure rates when treated with radiation therapy. The study found that tumors from African-American men were more likely to have indicators of increased sensitivity to radiation, leading to improved outcomes.
A large, long-term study found SBRT to be safe and effective for men with low- and intermediate-risk prostate cancer. The treatment delivered substantially larger doses of radiation per session, reducing the duration of treatment without increasing the risk of severe side effects.
The SPPORT trial found that adding pelvic lymph node treatment and short-term hormone therapy to standard treatment extends time before cancer spreads. This combination therapy resulted in higher freedom-from-progression rates and lower distant metastasis rates compared to standard treatments alone.
A large comparison study found that radiotherapy to the prostate improved failure-free survival but not overall survival in men with newly diagnosed metastatic prostate cancer and a low burden of disease. The treatment was well-tolerated, with only modest side effects.
Researchers at City of Hope have developed a synthetic DNA molecule that disables tumor defense systems while inducing immune responses, eliminating difficult-to-treat prostate cancer in experimental models. The novel two-step strategy relies on two opposite actions of the same 'hot and cold' molecule to remove obstacles to treating me...
A new test developed by scientists at the University of York can accurately identify life-threatening prostate cancers, which could lead to fewer unnecessary surgeries and radiotherapies. The test has shown a high accuracy rate of up to 92%, potentially reducing healthcare costs and side effects for patients.
Recent studies conducted by CHAAMPS reveal significant health disparities among black men, including racial disparities in hospitalizations for heart failure. Additionally, the organization aims to address violent encounters between police and young black men through community-based initiatives.
The new guideline recommends moderate hypofractionation (240-340 cGy) as an alternative to conventional fractionation for men with early-stage prostate cancer. Hypofractionated radiation therapy can be completed in four to five weeks, compared to eight to nine weeks for conventional radiation.
A new study finds that baseline PSA levels measured at midlife strongly predict total and aggressive prostate cancer in black men years later. The research suggests targeted screening based on a midlife PSA might identify black men at high risk while minimizing screening in those at low risk.
Researchers are developing a robot that can detect and treat prostate cancer more accurately, reducing the need for invasive procedures. The robot will guide a steerable flexible needle to target cancer cells, while AI and mathematical modeling ensure precise placement of radioactive material.
Researchers at UCLA have discovered that late-stage prostate and lung cancers share common molecular mechanisms. The study found that these cancers can evolve similarly, even from different organs, which could lead to the development of drugs to treat not just prostate and lung cancers but also small cell cancers of almost any organ.
Researchers have discovered a potential treatment for prostate cancer using riluzole, a drug approved for ALS treatment. The study found that riluzole promotes the degradation of androgen receptors, which drives prostate cancer growth.
A new pathology test using AI can accurately predict clinically significant prostate cancer disease progression following surgery, helping guide treatment decisions. The Precise MD post-op test reclassified 58% of intermediate risk patients as low risk and 42% as high risk for significant disease progression.
A new study finds that baseline PSA levels in black men between 40 and 60 can strongly predict future development of prostate cancer and its most aggressive forms. Elevated PSA levels are associated with increased risk, even among those within the normal range.
A Phase III clinical trial is enrolling men with metastatic Stage 4 prostate cancer to compare standard systemic therapy with or without surgery or radiation therapy. The goal is to delay disease progression and improve survival.
A recent study published in the journal Cancer found that patients with locally advanced prostate cancer who received a combination of prostate removal and radiation therapy had a higher rate of survival compared to those treated with radiation alone. The study analyzed data from over 13,000 men diagnosed with high-risk prostate cancer...
A survey of over 2,500 respondents found low awareness of urological conditions, particularly among men. Men are less knowledgeable about urological symptoms than women, and many do not take early signs seriously, leading to delayed diagnosis and potentially life-threatening consequences.
Researchers developed an mRNA-based nanotherapeutic to reintroduce functional copies of PTEN into cancer cells, restoring tumor suppressor function and killing cancer cells. The therapy showed significant suppression of tumor growth and progression in mouse models of prostate cancer.
A study estimates that prostate cancer screening and treatment for older men costs Medicare over $1.2 billion annually. The majority of this cost goes towards treating low-grade disease with Gleason scores of 6, which may not significantly impact life expectancy.
A research team at the University of Turku discovered a link between HOXB13 and CIP2A genes and aggressiveness of prostate cancer. The simultaneous expression of these two gene variants predisposes men to get prostate cancer earlier in life and stimulates tumor formation.
A recent study highlights the potential for misinterpretation of Prostate-Specific Membrane Antigen (PSMA) PET results, which can affect diagnostic accuracy and guide therapy. Researchers urge nuclear medicine physicians to analyze PSMA-ligand uptake in conjunction with lesion localization to avoid misdiagnosis.
International experts advise against routine PSA screening for prostate cancer, citing small benefits and potential harm. However, clinicians should engage in shared decision-making with patients considering screening, especially those at higher risk of prostate cancer death.
Researchers at Cedars-Sinai Medical Center discovered how hormone therapy can cause prostate cancer to spread by transforming some cancer cells into aggressive neuroendocrine cancer-type cells. A potential simple blood test may help predict when this type of therapy resistance will occur, according to the study.
Researchers discovered a link between ANO7 gene mutations and aggressive prostate cancer risk and severity, suggesting improved diagnosis and treatment options. The study found specific genetic mutations that correlated with increased disease risk and poorer survival rates.
Heavy alcohol consumption during adolescence and young adulthood may increase the odds of developing high-grade prostate cancer. Men who drank at least seven drinks per week between ages 15-19 had three times the odds of being diagnosed with clinically significant prostate cancer compared to non-drinkers.
Blocking POM121 transport inhibits tumor aggressiveness and restores chemotherapy efficacy in preclinical models. This study identifies nuclear pore proteins as effective anti-cancer targets for advanced prostate cancers, offering a new approach to target undruggable molecular drivers.
A low-protein diet during pregnancy and lactation may increase the risk of prostate cancer in offspring, according to a study with rats. The study found that females fed a low-protein diet had offspring with preneoplastic alterations capable of interfering with glandular function.
A team of scientists has developed a faster and more accurate way to test new treatments for the most aggressive form of prostate cancer. Lab-grown tumours derived from donor patient tumours enable researchers to test drug combinations quickly and efficiently, identifying those that cause the most striking reduction in tumour growth.
A blood test can predict which treatment is most likely to extend a patient's life with advanced prostate cancer. Researchers found that patients who tested positive for the protein AR-V7 responded best to taxane-based chemotherapy, while those who tested negative responded better to hormone-targeting therapy.
A study by University of Oulu researchers has identified novel genes and mechanisms associated with aggressive prostate cancer progression. The research suggests ways to improve risk stratification and clinical treatment for advanced prostate cancer.
Scientists have identified genetic errors common in metastatic prostate tumors, including alterations in the androgen receptor region. The study found that about 80% of aggressive tumors had similar genetic changes, which could lead to new treatment options for patients with aggressive forms of prostate cancer.
A new study found that eating an early supper and having a long interval between the last meal and sleep are associated with lower breast and prostate cancer risks. Participants who had supper before 9pm or slept 2 or more hours after supper had a reduced risk of developing these cancers.
A high-fat diet accelerates prostate cancer growth and increases immune cells that suppress the immune system. Anti-inflammatory drugs may have benefits for obese patients with prostate cancer.
The RESPOND study will explore the role of social stressors and genetics in developing prostate cancer among African-American men. The study aims to recruit 10,000 participants nationwide to understand the factors contributing to poor outcomes in this disease.
The RESPOND study, funded by $26.5 million grants, aims to understand why African-American men are at higher risk for developing aggressive forms of prostate cancer. Researchers will assess social stressors and genetics to identify genetic markers for the disease.
Researchers investigating genetic and environmental factors contributing to aggressive prostate cancer in African-American men, a population with a 15% lifetime risk compared to 10% for white men.
A new study has found that eating an early supper is associated with a lower risk of breast and prostate cancer. Participants who ate before 9pm had a 20% lower risk compared to those who ate late, suggesting the importance of meal timing in cancer prevention.
Football training has been linked to improved bone mineral density in elderly men with prostate cancer, particularly in those undergoing androgen deprivation therapy. The study found no association with body composition or physical functioning.
SourceWiley·JournalScandinavian Journal of Medicine and Science in Sports·DateJul 16, 2018
A new study found that a deadlier subtype of metastatic prostate cancer, called t-SCNC, constitutes about 17% of resistant cases. Researchers suggest that targeted drugs already in clinical trials could be effective in treating this subtype.
A new study published in European Urology found that high-intensity focused ultrasound (HIFU) treatment is as effective as surgery or radiotherapy in treating prostate cancer, with lower risks of side effects. After five years, the cancer survival rate from HIFU was 100%, comparable to surgery and radiotherapy.
Men treated with ICSI for infertility have a significantly higher risk of developing early-onset prostate cancer, which is considered more aggressive. The study found that this risk is associated with male sub-fertility, not the ICSI procedure itself.
A new form of immunotherapy has been found to reactivate the response to hormone treatment in advanced prostate cancer, a study in mice and human prostate cancer cells has found. The drug blocks a protein produced by immune cells, restoring sensitivity to hormone therapy and potentially improving outcomes for men with advanced disease.
A clinical trial found that 59% of patients with biochemical recurrence of prostate cancer had their clinical management changed by fluciclovine PET/CT imaging. The study detected disease in the prostate, pelvic lymph nodes, and less commonly, bone, guiding treatment decisions for men with recurrent prostate cancer.
Researchers found improved quality of life and reduced tumor spread in patients treated with LuPSMA therapy. PSMA PET imaging demonstrated exceptional responses, correlating with significant reductions in PSA levels.
Researchers discovered a molecular inhibitor that could help fight prostate cancer when resistance develops to CDK4/6 inhibitors. The study found that tumors become more aggressive and dependent on the MAPK-6 pathway when resistance occurs, making MEK inhibitors a potential therapeutic option.
A study presented at the SNMMI Annual Meeting found that early treatment of advanced prostate cancer with lutetium-177 radioligand therapy can significantly prolong life, with a median overall survival of 27 months. Patients who received first-line therapy also had the longest survival rates.
Researchers at Cleveland Clinic found that a common prostate cancer drug, abiraterone, yields high levels of a testosterone-like byproduct in men with advanced disease who have a specific genetic variant. This byproduct may trick androgen receptors into turning on pro-cancer pathways.
A study investigating combination checkpoint immunotherapy in lethal advanced prostate cancer revealed that genetic subsets of patients with AR-V7+ prostate cancer may benefit from treatment. One-quarter of patients achieved an objective response, and at least two remain alive for over 18 months.
Two Phase I/II clinical studies, PROter and PROfind, evaluate the safety and efficacy of radiolabeled PSMA-R2 for prostate cancer treatment. The trials assess tumor activity and patient response to treatment.
A new study found that a pattern of genetic changes in prostate tumours can predict which men are likely to benefit from immunotherapy. The research identified a distinct group of men with advanced prostate cancer whose tumours have biological features that make them responsive to immunotherapy drugs.
Researchers identified a new subtype of prostate cancer characterized by loss of the CDK12 gene, which was found to be more common in metastatic cases. Tumors with this alteration were responsive to immune checkpoint inhibitors, a type of immunotherapy treatment.
A new DNA test has identified 63 genetic variations that increase the risk of prostate cancer, with men inheriting these variants having a 5.7 times higher risk. The test combines multiple genetic variants to predict individual risk, offering hope for early detection and prevention.
Researchers have discovered 63 new genetic variations associated with higher risk of prostate cancer, enabling early and regular screening for men at increased risk. The findings represent the largest increase in genetic markers since their first identification in 2006.
Researchers identified 63 new genetic markers associated with prostate cancer risk in a global DNA analysis of over 140,000 men. The findings suggest that one percent of at-risk men are six times more likely to develop prostate cancer, highlighting the potential for genetic screening and prevention strategies.
A new sensor detects prostate cancer cells in blood samples with high efficiency, using a low-cost method that resembles Velcro. The device captures tumor cells from circulation, enabling doctors to diagnose the disease earlier and monitor its effectiveness.
A study of nearly 10,500 US prostate cancer patients found that more frequent PSA monitoring did not improve long-term survival rates. The research suggests that once-a-year monitoring may be sufficient for most patients.
According to a new analysis of over 8,000 patients, African-American men with advanced prostate cancer who received docetaxel-based therapies had a lower risk of death than white men. This finding is significant, as it challenges the long-held notion that racial disparities in prostate cancer survival are due to biological differences.
African-American men with advanced prostate cancer respond better to anti-androgen drugs and steroids than white men, according to a Duke University Medical Center study. The study suggests potential strategies for improving survival rates among black patients.